

ASX: CVB

26 October 2026

CurveBeam AI strengthens Board with NED appointment of Dan Pryor

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB) ("**CVB**", "**CurveBeam AI**" or the "**Company**"), a developer of point-of-care (PoC) specialised medical imaging (CT) equipment and AI enabled SaaS based clinical assessment solutions, is pleased to announce the appointment of Mr Dan Pryor as a Non-Executive Director effective 25 October 2026, bringing extensive experience in global medical devices, strategic transactions, capital allocation and corporate governance to the Company as it advances its commercialisation strategy.

Mr Pryor has more than 30 years of experience across the industrial and medical device sectors, including senior executive roles at Enovis Corporation (Orthopedics) and Danaher Corporation, as well as a senior investment role at The Carlyle Group. In his role as Executive Vice President at Enovis, he helped lead its transformation into a global medical technology platform through more than 50 acquisitions and divestitures representing over \$14 billion in enterprise value. His experience spans strategic transformation, mergers and acquisitions, divestitures and corporate development, providing a valuable combination of operational leadership and investment expertise.

He holds a Bachelor of Arts in Economics from Williams College and an MBA from Harvard Business School.

Mr Pryor's appointment comes at an important stage in CurveBeam AI's development as the Company seeks to accelerate commercial adoption of its weight-bearing CT (WBCT) technology and expand its software-enabled clinical assessment offerings across global orthopaedic markets.

CurveBeam AI CEO Greg Brown said: "We are delighted to welcome Dan to the CurveBeam AI Board. His experience spans global medical device leadership, especially in orthopaedics, strategic transactions, capital allocation and corporate governance. As we enter the next phase of our development, our priority is to translate our differentiated technology into broader commercial adoption. That requires disciplined capital allocation, strong strategic partnerships and a clear focus on execution. Dan's experience in building and transforming medical device businesses in orthopaedics will bring an important perspective to the Board as we pursue the opportunities ahead for HiRise™, BoneVue and our future platforms. We believe his contribution will help strengthen our strategic decision making and our focus on creating long term shareholder value."

Mr Pryor will also chair the Board's Audit & Risk Committee, strengthening the Company's financial oversight, risk management and governance capabilities as CurveBeam AI progresses its next phase of commercial development, and will join the Nomination and Remuneration Committee.

Mr Pryor's recent thought leadership on M&A and strategic partnerships in orthopedics further demonstrates his understanding of the competitive and consolidation dynamics shaping the sector. In two recent articles published by BONEZONE, he has explored how strategic collaboration between established industry participants, emerging technology companies and investors can accelerate innovation, create commercial opportunities and unlock value. This experience and perspective are particularly relevant to CurveBeam AI as the Company seeks to expand the

adoption of its weight-bearing CT technology, develop strategic partnerships with leading orthopaedic implant companies and pursue scalable commercialisation opportunities in the global orthopaedic market.

His articles include [How Innovation in Orthopedics Actually Happens](#) and [How Startups and Strategies Shape Orthopedic Innovation Together](#).

Dan Pryor commented: “I am pleased to be joining the Board of CurveBeam AI at an important stage in the Company’s development. CurveBeam AI has developed differentiated technology with significant potential across orthopaedics, and I see opportunities to build on this strong foundation through disciplined execution, strategic partnerships and a focused approach to commercialisation. I look forward to working with the Board and management team to help translate the Company’s intellectual property into sustainable commercial growth, while maintaining strong governance, financial discipline and a clear focus on long-term shareholder value.”

CurveBeam’s HiRise™ combines weight-bearing CT imaging with the potential for quantitative bone assessment, supporting a more comprehensive approach to orthopaedic imaging and surgical planning. BoneVue extends the Company’s software capabilities into CT-based BMD assessment, while SkyRise™ represents the Company’s next-generation imaging opportunity. Together, these technologies provide a platform for CurveBeam AI to pursue broader commercial partnerships and expand its role in orthopedic assessment and clinical decision support.

The board has approved an initial grant of 4.0 million share rights vesting over 3 years, and annual remuneration of US\$130,000 in annual share right grants (with annual share right grants subject to shareholder approval).

Release approved by the Board of Directors.

About CurveBeam AI Limited

CurveBeam AI Limited (ASX: CVB) develops, manufactures and sells specialised medical imaging (“CT”) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company’s flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

Forward-Looking Statements

This announcement contains certain forward-looking statements, including statements of intent, belief or current expectations with respect to the Company’s business and operations, market conditions, results of operations and financial condition. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied in such statements.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, CVB undertakes no obligation to update or revise any forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which such statements are based.

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au